What We Do
We employ the latest insights in tumor biology and immunology in our search for new molecular targets and development of new mechanisms for antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs) and small molecule programs.
Pipeline
Our diverse pipeline of proprietary next-generation ADCs and mAb therapeutics reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Clinical Program
Byondis’ clinical programs are developed in-house. Our rigorous review process for each R&D program is designed to ensure an innovative pipeline with a high likelihood of clinical success, without compromising safety.
Publications & Presentations
Novel developments are regularly published in highly ranked peer-reviewed journals.
Byondis’ Key Technologies
Byondis has a suite of proprietary technologies available to generate promising clinical candidates. This includes next generation ADCs containing our proprietary duocarmazine linker-drug (LD) technology ByonZine®.
Who We Are
At Byondis, we are dedicated to transforming the lives of those affected by cancer.
Research & Development
Our programs target intractable cancers and autoimmune diseases, with the aim of creating innovative, safe and effective targeted medicines, based on new biological and new chemical entities.
